REGISTERED COMPANY NUMBER: 07476120 (England and Wales) REGISTERED CHARITY NUMBER: 1142803
Trustees' Report and
Unaudited Financial Statements
for the Year Ended 31 December 2025
for
Global Sepsis Alliance
RAA Avalon Accounting Ltd 12 Park Lane Tilehurst Reading Berkshire RG31 5DL
Global Sepsis Alliance
Contents of the Financial Statements for the Year Ended 31 December 2025
| Page | |||
|---|---|---|---|
| Trustees' Report | 1 | to | 7 |
| Independent Examiner's Report | 8 | ||
| Statement of Financial Activities | 9 | ||
| Balance Sheet | 10 | to | 11 |
| Notes to the Financial Statements | 12 | to | 17 |
| Detailed Statement of Financial Activities | 18 | to | 19 |
Global Sepsis Alliance
Trustees' Report for the Year Ended 31 December 2025
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
Page 1
Global Sepsis Alliance
Trustees' Report for the Year Ended 31 December 2025
OBJECTIVES AND ACTIVITIES
Objectives and aims
Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by: - the provision of financial assistance, support, education, research, and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.
The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate
range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.
Ensuring Our Work Delivers Our Aims
The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees, Board, and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.
Review of Activities 2025
During 2025, the Global Sepsis Alliance (GSA) continued to strengthen its role as a global convener, advocate, and knowledge-sharing platform in the fight against sepsis. Through international partnerships, policy engagement, educational activities, and survivor involvement, GSA advanced its mission to reduce preventable sepsis deaths and disabilities worldwide.
The following activities represent the organization's most significant achievements during the year.
Global Advocacy and Policy Engagement
In February, GSA contributed to international policy discussions at the 156th Session of the World Health Organization (WHO) Executive Board in Geneva. GSA called on governments and global health stakeholders to prioritize sepsis within Universal Health Coverage packages and strengthen efforts to prevent, diagnose, and treat sepsis globally.
GSA also published a policy outlook entitled Investing in Sepsis Science for Future Pandemic Preparedness, highlighting the importance of sustained investment in sepsis research as a critical component of global health security.
In March, the European Sepsis Alliance (ESA), coordinated by GSA, held its 8th Annual Meeting at the European Parliament in Brussels, where a Call to Action was launched to encourage European policymakers to develop a coordinated response to sepsis across Europe.
In May, GSA convened the first-ever Official Side Event on Sepsis at the 78th World Health Assembly in Geneva in collaboration with multiple international partners, governments, and global health organizations. During the Assembly, GSA delivered official statements urging WHO Member States to recognize sepsis as a leading cause of preventable death and disability.
In September, GSA organized a side event during the 80th Session of the United Nations General Assembly in New York, further elevating sepsis on the global policy agenda.
Knowledge Sharing and Global Education
The 5th World Sepsis Congress, held in April, represented one of GSA's flagship activities. The free, fully virtual congress brought together almost 12,000 participants from more than 170 countries, with 68% of attendees joining from low- and middle-income countries.
The congress featured expert discussions on sepsis epidemiology, artificial intelligence, antimicrobial stewardship, integrated care pathways, innovations in diagnostics and treatment, and health systems strengthening. Importantly, it also amplified the voices of sepsis survivors and family members.
Page 2
Global Sepsis Alliance
Trustees' Report for the Year Ended 31 December 2025
Throughout the year, GSA expanded its educational offerings through multiple webinars addressing key topics, including antimicrobial stewardship, sepsis management in resource-limited settings, and the intersection between antimicrobial resistance and sepsis.
Survivor and Community Engagement
In April, GSA established the Global Sepsis Survivor Committee (GSSC), creating a formal mechanism for survivors and family members to contribute to GSA's activities and strategic priorities.
Throughout the year, GSA continued to share personal stories from sepsis survivors and families around the world, helping to raise awareness and ensure that lived experiences remained central to advocacy efforts. In November, GSA launched its Individual Membership Program, enabling survivors, healthcare professionals, researchers, advocates, and members of the public to directly support and participate in the organization's mission.
Strategic Partnerships and Global Collaboration
GSA strengthened existing partnerships and established new collaborations throughout 2025. In March, GSA announced a partnership with the International Fluid Academy to advance education and clinical collaboration in sepsis care. The organization also continued developing the Global Sepsis Innovations Platform (GSIP), a multi-stakeholder initiative focused on accelerating innovation in sepsis prevention, diagnostics, treatment, and health system implementation. In February, GSA hosted a symposium in Berlin entitled "Overcoming Silos by Synergizing the Fight Against Sepsis and Antimicrobial Resistance", bringing together experts from multiple disciplines to strengthen collaboration between the global sepsis and antimicrobial resistance communities.
Throughout the year, GSA actively participated in international health forums and maintained engagement with WHO, governments, parliamentarians, healthcare organizations, research institutions, and civil society partners to advance the objectives of the 2030 Global Agenda for Sepsis.
World Sepsis Day
World Sepsis Day in September remained one of GSA's most impactful awareness initiatives. Hundreds of events were organized worldwide by partners and supporters, helping to raise awareness of sepsis among healthcare professionals, policymakers, patients, and the general public.
GSA itself organized three international events, including a central press conference in Berlin and global policy events in Geneva and New York. The campaign also received high-level support from WHO Director-General Dr Tedros Adhanom Ghebreyesus, who delivered a video address to the global sepsis community.
Organizational Development
In June, GSA welcomed its newly elected Board for the 2025-2028 term. Throughout the year, the organization maintained regular engagement with its member organizations, Regional Sepsis Alliances, partners, and sponsors to strengthen governance, coordinate strategic priorities, and build momentum for future initiatives.
Collectively, these activities have further strengthened GSA's position as a leading global organization dedicated to reducing the burden of sepsis through advocacy, education, partnership building, survivor engagement, and policy development.
How Our Activities Deliver Public Benefit
The Global Sepsis Alliance exists to reduce the global burden of sepsis through advocacy, education, innovation, and international collaboration. Our activities deliver clear public benefit by raising awareness of sepsis among healthcare professionals, policymakers, and the general public; promoting early recognition and timely treatment; supporting survivors and families; and contributing to the development of global health policy. Through free access to high-quality educational resources such as the World Sepsis Congress, collaboration with the World Health Organization and national governments, and support for regional alliances, we help improve sepsis outcomes worldwide - particularly in low- and middle-income countries, where the burden is greatest.
Our work aligns with public health priorities, advances the Sustainable Development Goals, and ultimately saves lives by informing and empowering both professionals and communities to act on sepsis.
Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly.
Page 3
Global Sepsis Alliance
Trustees' Report for the Year Ended 31 December 2025
Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.
We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.
What Examples Exist of Who Has Benefited?
A wide range of individuals and communities have benefited from the work of the Global Sepsis Alliance. Healthcare professionals worldwide - particularly in low- and middle-income countries - have gained free access to the latest clinical knowledge and research through our educational events, such as the World Sepsis Congress and thematic symposia. Policymakers and public health authorities have drawn on our guidance and advocacy to develop or enhance national sepsis strategies, as seen with the SEPSIS Act in the United States and the launch of the 2030 Global Agenda for Sepsis. Sepsis survivors and their families have also benefited through platforms that amplify their voices, connect them with support networks, and raise public awareness. Additionally, organizations such as the Caribbean Sepsis and AMR Alliance have emerged with GSA support, enabling local responses to regional sepsis challenges. Collectively, these examples demonstrate how our work directly supports professionals, policymakers, and the public in reducing the harm caused by sepsis.
Page 4
Global Sepsis Alliance
Trustees' Report for the Year Ended 31 December 2025
PLANS FOR FUTURE PERIODS
In 2026, the Global Sepsis Alliance (GSA) will continue to strengthen its position as a global leader in sepsis advocacy, education, and partnership building, with a particular focus on translating increased international awareness into sustained policy action and measurable health system improvements.
A key priority will be to further elevate sepsis on regional and global political agendas. GSA will continue its engagement with the World Health Organization, United Nations agencies, governments, and international partners to promote the integration of sepsis into broader health system strengthening, pandemic preparedness, and antimicrobial resistance strategies.
The European Sepsis Alliance will intensify its advocacy efforts at the European level, including engagement with the Irish Presidency of the Council of the European Union, with the aim of advancing coordinated action on sepsis across Europe.
GSA will continue to expand its educational activities through webinars, expert discussions, and freely accessible digital resources, ensuring that healthcare professionals, researchers, policymakers, and patient advocates worldwide have access to current evidence and best practices in sepsis prevention, diagnosis, and treatment.
A major priority for 2026 will be the organization and execution of the 6th World Sepsis Congress, to be held in April 2026 under the theme "Universal Sepsis Care for Newborns, Children, and Women". As GSA's flagship educational initiative, the free, fully virtual congress will bring together healthcare professionals, researchers, policymakers, patient advocates, survivors, and representatives from international organizations from around the world.
The congress will focus on improving equitable access to high-quality sepsis prevention, diagnosis, and treatment for some of the most vulnerable populations, while promoting multidisciplinary collaboration and the exchange of best practices. By ensuring unrestricted global access, GSA aims to strengthen knowledge sharing, support capacity building, and advance progress towards universal sepsis care worldwide.
The organization will further develop the Global Sepsis Innovations Platform (GSIP) to accelerate collaboration between researchers, clinicians, industry partners, innovators, and people with lived experience. Particular emphasis will be placed on supporting innovations in diagnostics, artificial intelligence, implementation science, and health system delivery.
Building on the successful establishment of the Global Sepsis Survivor Committee, GSA will strengthen survivor engagement and ensure that the perspectives of survivors and family members remain central to its advocacy and program development.
The Individual Membership Program, launched in 2025, will continue to be expanded to foster a broader global community of supporters and increase opportunities for participation in GSA activities.
World Sepsis Day will remain a flagship awareness initiative in 2026, with GSA supporting global campaigns and coordinating international events to increase public awareness and encourage policy action at national and international levels.
The organization will also continue to strengthen its network of member organizations, Regional Sepsis Alliances, and strategic partners, with the aim of fostering greater collaboration and accelerating progress towards reducing preventable sepsis deaths and disabilities worldwide.
Through these activities, GSA aims to further advance its vision of a world free of sepsis and contribute to achieving sustainable, equitable improvements in sepsis prevention, recognition, and care globally.
STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.
Page 5
Global Sepsis Alliance
Trustees' Report for the Year Ended 31 December 2025
STRUCTURE, GOVERNANCE AND MANAGEMENT
Recruitment and appointment of new trustees
The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.
Induction and training of new trustees
The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:
-
The obligations of Executive Board members.
-
The main documents which set out the operational framework for the charity including the Memorandum and Articles.
-
Resourcing and the current financial position as set out in the latest published accounts.
-
Future plans and objectives.
Risk management
The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.
REFERENCE AND ADMINISTRATIVE DETAILS
Registered Company number
07476120 (England and Wales)
Registered Charity number
1142803
Registered office
12 Park Lane Tilehurst Reading Berkshire RG31 5DL
Trustees
Mr Philip Taylor Director Dr. Konrad Anton Reinhart Director Dr. Darren Ron Daniels Director
Company Secretary
Mr Philip Taylor
Page 6
Global Sepsis Alliance
Trustees' Report for the Year Ended 31 December 2025
REFERENCE AND ADMINISTRATIVE DETAILS
Independent Examiner
RAA Avalon Accounting Ltd 12 Park Lane Tilehurst Reading Berkshire RG31 5DL
Solicitors
Russell-Cooke LLP 2 Putney Hill London SW15 6AB
Bankers
Barclays Bank plc Commerzbank Aldermaston Road Fischergasse 10 Tadley 07743 Basingstoke Jena Hampshire Germany RG26 4QA
Executive Committee
Abdulelah Alhawsawi Dennis Kredler Imrana Malik Maha Aljuaid Ron Daniels Shevin Jacob
Board Members
Abdulelah Alhawsawi, Alison Fox-Robichaud, Ally Hossain, Andrew Argent, Antonio Artigas, Ciaran Staunton, Dennis Kredler, Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Maha Aljuaid, Mitchell Levy, Naoyuki M at s u d a,
Rafael Barberena Moraes, Ron Daniels, Sheila Myatra, Shevin Jacob, Steve McGloughlin, Tex Kissoon, Ulrika Knutsson.
Approved by order of the board of trustees on ............................................. and signed on its behalf by:
......................................................................
Mr Philip Taylor - Trustee
Page 7
Independent Examiner's Report to the Trustees of Global Sepsis Alliance
Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2025.
Responsibilities and basis of report
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.
Independent examiner's statement
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Caroline Brazier
RAA Avalon Accounting Ltd 12 Park Lane Tilehurst Reading Berkshire RG31 5DL
Date: .............................................
Page 8
Global Sepsis Alliance
Statement of Financial Activities for the Year Ended 31 December 2025
| 2025 Unrestricted fund Notes £ Income and endowments from Donations and legacies 2 308,583 Other trading activities 3 56,617 Total 365,200 Expenditure on Raising funds 4 325,586 NET INCOME/(EXPENDITURE) 39,614 Reconciliation of funds Total funds brought forward 146,548 Total funds carried forward 186,162 |
2024 Total funds £ 67,357 51,865 119,222 448,677 (329,455) 476,003 146,548 |
|---|---|
The notes form part of these financial statements
Page 9
Global Sepsis Alliance
Balance Sheet 31 December 2025
| 2025 Unrestricted fund Notes £ Fixed assets Tangible assets 9 7,373 Current assets Debtors 10 157,458 Cash at bank 25,009 182,467 Creditors Amounts falling due within one year 11 (3,678) Net current assets 178,789 Total assets less current liabilities 186,162 NET ASSETS 186,162 Funds 12 Unrestricted funds 186,162 Total funds 186,162 |
2024 Total funds £ 9,831 127,569 27,088 154,657 (17,940) 136,717 146,548 146,548 146,548 146,548 |
|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.
The trustees acknowledge their responsibilities for
-
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
-
(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
The notes form part of these financial statements
continued...
Page 10
Global Sepsis Alliance
Balance Sheet - continued 31 December 2025
These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by:
............................................. Mr Philip Taylor - Trustee
The notes form part of these financial statements
Page 11
Global Sepsis Alliance
Notes to the Financial Statements for the Year Ended 31 December 2025
1. ACCOUNTING POLICIES
BASIS OF PREPARING THE FINANCIAL STATEMENTS
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
INCOME
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.
EXPENDITURE
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
TANGIBLE FIXED ASSETS
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
| Plant and machinery | - 25% on reducing balance |
|---|---|
| Fixtures and fittings | - 25% on reducing balance |
| Computer equipment | - 25% on reducing balance |
TAXATION
The charity is exempt from corporation tax on its charitable activities.
FUND ACCOUNTING
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
continued...
Page 12
Global Sepsis Alliance
Notes to the Financial Statements - continued for the Year Ended 31 December 2025
| 2. | DONATIONS AND LEGACIES | ||||
|---|---|---|---|---|---|
| 2025 | 2024 | ||||
| £ | £ | ||||
| Donations | 308,583 | 67,357 | |||
| 3. | OTHER TRADING ACTIVITIES | ||||
| 2025 | 2024 | ||||
| £ | £ | ||||
| Sponsorships | 56,617 | 51,865 | |||
| 4. | RAISING FUNDS | ||||
| RAISING DONATIONS AND LEGACIES | |||||
| 2025 | 2024 | ||||
| £ | £ | ||||
| Postage and stationery | 1,423 | 3,498 | |||
| Other direct cost | 8,811 | 1,553 | |||
| Travel subsistence & accommodation | 18,363 | 11,339 | |||
| Event costs | 57,692 | 62,279 | |||
| Support costs | 239,297 | 370,008 | |||
| 325,586 | 448,677 | ||||
| 5. | SUPPORT COSTS | ||||
| Information | |||||
| Management | Finance | technology | |||
| £ | £ | £ | |||
| Raising donations and legacies | 221,121 | 825 | 5,833 | ||
| Governance | |||||
| Other | Other 2 | costs | Totals | ||
| £ | £ | £ | £ | ||
| Raising donations and legacies | 2,458 | 3,725 | 5,335 | 239,297 | |
| 6. | NET INCOME/(EXPENDITURE) | ||||
| Net income/(expenditure) is stated after charging/(crediting): | |||||
| 2025 | 2024 | ||||
| £ | £ | ||||
| Depreciation - owned assets | 2,458 | 3,277 |
continued...
Page 13
Global Sepsis Alliance
Notes to the Financial Statements - continued for the Year Ended 31 December 2025
7. TRUSTEES' REMUNERATION AND BENEFITS
There were no trustees' remuneration or other benefits for the year ended 31 December 2025 nor for the year ended 31 December 2024.
TRUSTEES' EXPENSES
There were no trustees' expenses paid for the year ended 31 December 2025 nor for the year ended 31 December 2024.
8. STAFF COSTS
| STAFF COSTS | ||
|---|---|---|
| Wages and salaries | 2025 £ 150,906 150,906 |
2024 £ 238,053 |
| 238,053 |
The average monthly number of employees during the year was as follows:
2025 2024
No employees received emoluments in excess of £60,000.
9. TANGIBLE FIXED ASSETS
| Fixtures Plant and and Computer machinery fittings equipment £ £ £ COST At 1 January 2025 and 31 December 2025 1,710 8,172 25,238 DEPRECIATION At 1 January 2025 879 6,872 17,538 Charge for year 208 325 1,925 At 31 December 2025 1,087 7,197 19,463 NET BOOK VALUE At 31 December 2025 623 975 5,775 At 31 December 2024 831 1,300 7,700 |
Totals £ 35,120 |
|---|---|
| 25,289 2,458 |
|
| 27,747 | |
| 7,373 | |
| 9,831 |
continued...
Page 14
Global Sepsis Alliance
| Notes to the Financial Statements-continued for the Year Ended 31 December 2025 10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR Trade debtors Investment VAT 11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR Social security and other taxes Other creditors Net wages Accrued expenses 12. MOVEMENT IN FUNDS At 1.1.25 £ Unrestricted funds General fund 146,548 TOTAL FUNDS 146,548 Net movement in funds, included in the above are as follows: Incoming resources £ Unrestricted funds General fund 365,200 TOTAL FUNDS 365,200 |
2025 2024 £ £ 137,894 108,037 18,639 18,639 925 893 157,458 127,569 2025 2024 £ £ 1,574 3,832 94 - - 12,248 2,010 1,860 3,678 17,940 Net movement At in funds 31.12.25 £ £ 39,614 186,162 39,614 186,162 Resources Movement expended in funds £ £ (325,586) 39,614 (325,586) 39,614 |
|---|---|
Page 15
continued...
Global Sepsis Alliance
Notes to the Financial Statements - continued for the Year Ended 31 December 2025
12. MOVEMENT IN FUNDS - continued
Comparatives for movement in funds
| Unrestricted funds General fund TOTAL FUNDS |
At 1.1.24 £ 476,003 476,003 |
Net movement in funds £ (329,455) (329,455) |
At 31.12.24 £ 146,548 |
|---|---|---|---|
| 146,548 |
Comparative net movement in funds, included in the above are as follows:
| Unrestricted funds General fund TOTAL FUNDS |
Incoming resources £ 119,222 119,222 |
Resources Movement expended in funds £ £ (448,677) (329,455) (448,677) (329,455) |
|---|---|---|
A current year 12 months and prior year 12 months combined position is as follows:
| Unrestricted funds General fund TOTAL FUNDS |
At 1.1.24 £ 476,003 476,003 |
Net movement in funds £ (289,841) (289,841) |
At 31.12.25 £ 186,162 |
|---|---|---|---|
| 186,162 |
A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:
| Unrestricted funds General fund TOTAL FUNDS |
Incoming resources £ 484,422 484,422 |
Resources Movement expended in funds £ £ (774,263) (289,841) (774,263) (289,841) |
|---|---|---|
Page 16
continued...
Global Sepsis Alliance
Notes to the Financial Statements - continued for the Year Ended 31 December 2025
13. RELATED PARTY DISCLOSURES
Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,325 (PY - £3,600). Mr. Philip Taylor is common director in both company.
Page 17
Global Sepsis Alliance
| Income and endowments Donations and legacies Donations Other trading activities Sponsorships Total incoming resources Expenditure Raising donations and legacies Postage and stationery Other direct cost Travel subsistence & accommodation Event costs Support costs Management Wages Computer Cost Insurance Office Rent Staff welfare Telephone Advertising Office cost Bookkeeping Consultancy Foreign Exchange Loss Finance Light and heat Sundry Expense Bank charges Paypal charges |
Detailed Statement of Financial Activities for the Year Ended 31 December 2025 |
2025 £ 308,583 56,617 365,200 1,423 8,811 18,363 57,692 86,289 150,906 3,670 34,757 17,144 - 861 1,656 - 1,224 7,393 3,510 221,121 275 34 364 152 825 |
2024 £ 67,357 51,865 |
|---|---|---|---|
| 119,222 3,498 1,553 11,339 62,279 |
|||
| 78,669 238,053 6,155 49,719 15,789 240 813 - 719 1,035 35,501 4,892 |
|||
| 352,916 120 - 286 102 |
|||
| 508 |
This page does not form part of the statutory financial statements
Page 18
Global Sepsis Alliance
| Finance Information technology Website development Other Plant and machinery Fixtures and fittings Computer equipment Other 2 Subscription Governance costs Accountancy fees Secretary Total resources expended Net income/(expenditure) |
Detailed Statement of Financial Activities for the Year Ended 31 December 2025 |
2025 £ 5,833 208 325 1,925 2,458 3,725 2,010 3,325 5,335 325,586 39,614 |
2024 £ 5,866 277 433 2,567 3,277 1,981 1,860 3,600 5,460 448,677 (329,455) |
|---|---|---|---|
This page does not form part of the statutory financial statements
Page 19